Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

8.090 +0.090 (+1.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Via Benzinga
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022
Upgrades 
Via Benzinga
Expert Ratings for Bicycle Therapeutics
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics's (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83... 
Via Benzinga
Bicycle Therapeutics: Q2 Earnings Insights
  Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
From Bicycle Therapeutics plc
Via Business Wire
Analyst Ratings for Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Bicycle Therapeutics
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
  
Via Benzinga
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
From Bicycle Therapeutics plc
Via Business Wire
Where Bicycle Therapeutics Stands With Analysts
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
From Bicycle Therapeutics plc
Via Business Wire
Where Bicycle Therapeutics Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Bicycle Therapeutics (NASDAQ:BCYC) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 16.4% to $0.89 during Friday's pre-market session. The market value of their outstanding shares is at $47.6 million. As per the press... 
Via Benzinga
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
From Bicycle Therapeutics plc
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows. 
Via Benzinga
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
Bicycle Therapeutics's Return On Capital Employed Overview
Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, resulting in a 52.82% decrease from last quarter. 
Via Benzinga
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Shares of Bicycle Therapeutics... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million. 
Via Benzinga
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.